What is the level of liabilities of Crossject this year?
Crossject has a debt balance of 26.85 M EUR this year.
Crossject Liabilities 2024
Crossject Liabilities
26.85 M EUR
Crossject Dividend yield
Ticker
ALCJ.PA
ISIN
FR0011716265
WKN
A1XEH4
In 2024, Crossject's total liabilities amounted to 26.85 M EUR, a 18.29% difference from the 22.7 M EUR total liabilities in the previous year.
Crossject Aktienanalyse
What does Crossject do?
Crossject SA is a company that specializes in the development and manufacturing of innovative drug delivery systems. The company was founded in 2006 by a team of professionals with the goal of changing the way medications are administered. Crossject's history began with the development of a unique drug delivery system called ZENEO. This system is based on a proprietary technology called "Needle Free Injection" that allows for needle-free and painless medication administration. The technology is safe, easy to use, and enables the administration of liquid medications and even solids in the form of suspensions. Crossject specializes in the application of this technology and develops products in various areas, including adrenaline for the treatment of life-threatening allergic reactions, methotrexate for the treatment of cancer, and anti-inflammatory medications for the treatment of asthma and COPD. The business model of Crossject is based on the development and commercialization of products based on the ZENEO technology. The company collaborates with a range of partners to bring its products to market, including pharmaceutical companies and other drug manufacturers. Crossject aims to sell its products worldwide and already has distribution partners in various countries around the world. Crossject is also committed to advancing the development of new products based on this technology. The company invests a significant portion of its revenue in research and development and works closely with academic institutions and other research facilities to improve its technology and products. Crossject's product offering includes a wide range of medications used for the treatment of various conditions. One example is the adrenaline injection system developed for the rapid and effective treatment of anaphylactic shocks that can occur as severe allergic reactions in people with food allergies, insect venom allergies, or drug allergies. The system does not require a needle and is therefore easy and safe to handle. Another example is the methotrexate injection for the treatment of cancer and autoimmune diseases such as rheumatoid arthritis and psoriasis. Crossject has also developed a range of products to combat asthma and chronic obstructive pulmonary disease (COPD). In 2019, the company received regulatory approval for its first commercial ZENEO product as an emergency treatment for migraines. This product is a fast-acting migraine therapy that is administered subcutaneously to quickly and effectively relieve pain and accompanying symptoms of migraines. In summary, Crossject is an innovative company specializing in the development and commercialization of drug delivery systems. The company utilizes a proprietary technology that allows for needle-free and painless medication administration and collaborates closely with partners to sell its products worldwide. Crossject continues to invest in research and development to bring new products based on its technology to market and establish itself as a leading company in its field. Crossject ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing Crossject's Liabilities
Crossject's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Crossject's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing Crossject's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
Crossject's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in Crossject’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about Crossject Stock
What were the liabilities of Crossject compared to the previous year?
The liabilities of Crossject have increased by 18.29% increased compared to the previous year.
What are the consequences of high debt for investors of Crossject?
High liabilities can pose a risk for investors of Crossject, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in Crossject?
Low liabilities mean that Crossject has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of Crossject affect the company?
An increase in liabilities of Crossject can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of Crossject affect the company?
A decrease in the liabilities of Crossject can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of Crossject?
Some factors that can influence the liabilities of Crossject include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of Crossject so important for investors?
The liabilities of Crossject are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can Crossject take to modify the liabilities?
To change its liabilities, Crossject can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does Crossject pay?
Over the past 12 months, Crossject paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Crossject is expected to pay a dividend of 0 EUR.
What is the dividend yield of Crossject?
The current dividend yield of Crossject is .
When does Crossject pay dividends?
Crossject pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Crossject?
Crossject paid dividends every year for the past 0 years.
What is the dividend of Crossject?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Crossject located?
Crossject is assigned to the 'Health' sector.
Wann musste ich die Aktien von Crossject kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Crossject from 6/4/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 6/4/2024.
When did Crossject pay the last dividend?
The last dividend was paid out on 6/4/2024.
What was the dividend of Crossject in the year 2023?
In the year 2023, Crossject distributed 0 EUR as dividends.
In which currency does Crossject pay out the dividend?
The dividends of Crossject are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Crossject
Our stock analysis for Crossject Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Crossject Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
